Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 1/20 | 0.65 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CCNC | P24863 | 6/20 | 0.48 |
| ▸ | CDK8 | P49336 | 6/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | MYLK | Q15746 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | CILK1 | Q9UPZ9 | 1/20 | 0.48 |
| ▸ | CDK11A | Q9UQ88 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 2/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1687452 | 0.85 | PRKCZ (0.63) | PRKCZCYP11B1CYP11B2CYP2D6CYP2C9 | |
| SCHEMBL28212097 | 0.84 | PRKCZ (0.58) | PRKCZCYP11B1CYP11B2CYP2D6CYP2C9 | |
| SCHEMBL12074301 | 0.82 | PRKCZ (0.73) | PRKCZCYP11B1CYP11B2CYP2D6CYP2C9 | |
| SCHEMBL6243938 | 0.81 | PRKCZ (0.72) | PRKCZCYP11B1CYP11B2CYP2D6CYP2C9 | |
| SCHEMBL29501875 | 0.81 | PRKCZ (0.72) | PRKCZCYP11B1CYP11B2CYP2D6CYP2C9 | |
| SCHEMBL2774270 | 0.81 | PRKCZ (0.57) | PRKCZCYP11B1CYP11B2CYP2D6CYP2C9 | |
| SCHEMBL10806364 | 0.79 | PRKCZ (0.69) | PRKCZCYP11B1CYP11B2CYP2D6CYP2C9 | |
| SCHEMBL12386960 | 0.79 | PRKCZ (0.69) | PRKCZCYP11B1CYP11B2CYP2D6CYP2C9 | |
| SCHEMBL526801 | 0.79 | PRKCZ (1.00) | PRKCZCYP11B1CYP11B2CYP2D6CYP2C9 | |
| SCHEMBL38660559 | 0.79 | PRKCZ (0.69) | PRKCZCYP11B1CYP11B2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590321-B1 | ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY | SANOFI AVENTIS (FR) | 2010-04-28 | — | — | EP | disclosed |
| US-7632850-B2 | 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS | SANOFI-AVENTIS (FR) | 2009-12-15 | — | — | US | disclosed |
| US-20060014830-A1 | Arylalkylcarbamate derivatives production and use thereof in therapy | SANOFI-AVENTIS (FR) | 2006-01-19 | — | — | US | disclosed |
| EP-1590321-A2 | ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY | Sanofi-Aventis (FR) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004067498-A2 | ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014830-A1 | Arylalkylcarbamate derivatives production and use thereof in therapy | CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C5 | PRKCZ 1694/4885CYP11B1 114/4885CYP11B2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.